Alnylam Pharmaceuticals (ALNY) extending rally in final stage from April-2025 low
|Alnylam Pharmaceuticals Inc., (ALNY) discovers, develops & commercializes therapeutics based on ribonucleic acid interference. It comes under Healthcare – Biotech sector & trades as “ALNY” ticker at Nasdaq.
As discussed in the last article, ALNY ended (4) pullback at $442.51 low & resume higher in (5). It favors rally in (5) towards $494.95 – $511.13 area as minimum extension to extend April cycle. It already reached the minimum level expected in last article, so chasing rally is risky now. But we like to buy the next correction in ((4)) at extreme area, when reach against April-2025 low.
ALNY – Elliott Wave latest weekly view
It ended ((I)) at $140 high since inception in June-2025 & ((II)) pullback at $31.38 low in October-2016. Above there, it is showing nest as the part of (III) of ((III)). It placed (I) of ((III)) at $153.99 high in March-2018 & (II) at $60.27 low in December-2018. Within (III), it placed I at $242.97 high in December-2022 as diagonal & II at $141.97 low in April-2024. It ended ((1)) at $212 high, ((2)) at $117.58 low, ((3)) at $236.80 high, ((4)) at $181.65 low & ((5)) at $242.97 high. It corrected II in zigzag correction ended at 0.50 Fibonacci retracement of I.
ALNY – Elliott Wave view from 9.08.2025
Above April-2024 low of II, it placed ((1)) of III at $304.39 high & ((2)) at $205.87 low on 4.07.2025 low. Currently, it favors rally in ((3)) of III & reached 1.618 Fib extension of ((1)). Yet, it expects small upside to finish it before correcting next in ((4)). Within ((3)), it placed (1) at $333.70 high, (2) at $309.57 low, (3) at $469.81 high, (4) at $442.51 low & favors rally in (5). It expects rally in (5) towards $494.95 – $511.13 area to finish ((3)) before correcting in ((4)). If it breaks above $511.13, then it can extend up to $570.76 to finish ((3)). Chasing longs can be risky now. But we like to buy the next correction in ((4)) in 3, 7 or 11 swings against 4.07.2025 low.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.